CalciMedica Raises $15 Million to support ongoing clinical trials in patients with COVID-19 pneumonia

BY      |     May 22, 2020

CalciMedica, a clinical-stage biotechnology company targeting CRAC channels for the treatment of inflammatory diseases, announced it had raised $15 million in a Series C financing round led by Valence Life Sciences.

The funds from this Series C financing will be used to advance ongoing clinical trials evaluating CRAC channel inhibitor, Auxora, in patients with COVID-19 pneumonia as well as to speed up commercial manufacturing for the drug.

Read the press release here.

Read more about CalciMedica here.

Image by Gerd Altmann from Pixabay

Comments? Questions? Suggestions?

If you have any comments, questions or suggestions concerning this article, feel free to email me at
Alternatively, you can leave your comments on LinkedIn or Twitter.